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Purpose: How modern cardiac sparing techniques and beam delivery systems using
advanced x-ray and proton beam therapy (PBT) can reduce incidental radiation exposure
doses to cardiac and pulmonary organs individually or in any combination is poorly
investigated.
Methods: Among 15 patients with left-sided breast cancer, partial wide tangential 3D-
conformal radiotherapy (3DCRT) delivered in conventional fractionation (CF) or
hypofractionated (HF) schedules; PBT delivered in a CF schedule; and volumetric
modulated arc therapy (VMAT) delivered in an HF schedule, each under continuous
positive airway pressure (CPAP) and free-breathing (FB) conditions, were examined.
Target volume coverage and doses to organs-at-risk (OARs) were calculated for each
technique. Outcomes were compared with one-way analysis of variance and the
Bonferroni test, with p-values <0.05 considered significant.
Results: Target volume coverage was within acceptable levels in all interventions, except
for the internal mammary lymph node D95 (99% in PBT, 90% in VMAT-CPAP, 84% in
VMAT-FB, and 74% in 3DCRT). The mean heart dose (MHD) was the lowest in PBT (<1
Gy) and VMAT-CPAP (2.2 Gy) and the highest in 3DCRT with CF/FB (7.8 Gy), respectively.
The mean lung dose (MLD) was the highest in 3DCRT-CF-FB (20 Gy) and the lowest in
both VMAT-HF-CPAP and PBT (approximately 5–6 Gy). VMAT-HF-CPAP and PBT
delivered a comparable maximum dose to the left ascending artery (7.2 and 6.13 Gy,
respectively).
Conclusions: Both proton and VMAT in combination with CPAP can minimize the
radiation exposure to heart and lung with optimal target coverage in regional RT for left-
sided breast cancer. The clinical relevance of these differences is yet to be elucidated.April 2021 | Volume 11 | Article 6453281
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Modern multi-disciplinary treatment for breast cancer, including
radiation therapy (RT), has improved patients’ long-term
survival rates (1). Concurrently, delayed side effects associated
with RT are gaining more importance (2–4). Recent studies have
reported that the risk of secondary lung cancer and
cardiovascular toxicity is associated with the mean radiation
dose delivered to the heart and lung (5). According to Darby
et al., the risk of major coronary events increases linearly by 7.4%
per 1-Gy increase in the mean heart dose (MHD) (6). The use of
comprehensive regional nodal irradiation (RNI) in RT has
increased after evidence from landmark trials became available
(7, 8). However, extended RT increases the MHD, thus
increasing the risk of major coronary events (9).
Recently, RT techniques such as deep inspiration breath hold
(DIBH), prone RT, cardiac blocking, and continuous positive
airway pressure (CPAP)—a new alternative to the DIBH
technique—have been introduced to help reduce the MHD (10,
11). Fixed-beam intensity-modulated radiotherapy (IMRT),
volumetric modulated arc therapy (VMAT), and proton beam
therapy (PBT) can also help reduce the MHD. In light of the
accumulating evidence regarding the safety and effectiveness of
hypofractionated radiotherapy (HF-RT), a 3-week schedule of 40
Gy in 15 fractions is being increasingly selected in the treatment
of breast cancer, especially during the current coronavirus
disease (COVID-19) pandemic (12). Rotational IMRT, such as
VMAT, has been suggested to reduce the dose to cardiac
substructures in the hypofractionated (HF) group (13).
However, how cardiac sparing techniques, IMRT/PBT, and
HF-RT affect dose avoidance to the organs-at-risk (OARs)
individually or in any combination is poorly understood.
This study aimed to compare target volume coverage and
dose to OARs, including cardiac and pulmonary doses, in eight
combinations of different RT techniques and dose schedules
[three-dimensional conformal RT (3DCRT), VMAT, and PBT,
with and without CPAP, delivered in a conventional
fractionation (CF) or HF schedule] to establish an optimal
technique for RNI in the modern era.MATERIALS AND METHODS
Following approval by the Institutional Review Board of Yonsei
University Hospital (No. 4-2020-1163), 15 patients with left-
sided breast cancer treated with regional nodal RT between April
and May 2020 were included. The requirement for informed
consent was waived owing to the study’s retrospective
nature. Three patients had undergone mastectomy without
reconstruction, while the remaining patients had undergonein.org 2lumpectomy. DIBH is associated with some practical
challenges (such as prolonged daily treatment time and the
requirement of a patient’s cooperation with high compliance).
Therefore, we have used CPAP as an alternative to DIBH since
2020 (14).
All patients underwent computed tomography (CT) with
free-breathing (FB) and CPAP. During RT simulation, CPAP
was gradually increased to the highest level tolerated by the
patient. Clinical target volumes (CTVs) for the breast and
thoracic wall were delineated for each CT image, utilizing the
ventral side of the major pectoral muscle, skin, and the medial
mammary branches of the internal thoracic artery as borders.
CTVs of the breast axillary lymph nodes (AXL1, AXL2, and
AXL3), supraclavicular lymph nodes (SCLs), and internal
mammary lymph nodes (IMNs) were also delineated
separately. The extent of RNI was modified at the physician’s
discretion. AXL1 or AXL2 were spared for seven patients.
Planning target volumes (PTVs) were generated with non-
uniform margins of 3–5-mm based on CTVs, maintaining a
minimum distance of 3–5 mm from the skin and lungs. OARs,
including the heart, left anterior descending artery (LAD),
ipsilateral lung, contralateral breast, skin, and esophagus
were delineated.
Eight plans were generated for each patient: 3DCRT in CF
and HF schedules, VMAT in an HF schedule, and PBT in a CF
schedule, using FB- and CPAP-based CT scans. Moreover,
3DCRT in a CF schedule was planned at a dose of 50.0 Gy in
25 fractions, followed by 5 fractions of sequential boost
irradiation at 2.0 Gy per fraction. Meanwhile, 3DCRT in an
HF schedule was set to 40.05 Gy in 15 fractions, followed by 5
fractions of sequential boost irradiation at 2.0 Gy per fraction.
VMAT in an HF schedule was planned as 40.05 Gy in 15
fractions, with simultaneous integral boost (SIB) to targets at
7.95 Gy (a total of 48.0 Gy for boost volume). PBT in CF was
planned as 25 fractions of 50.0 Gy (considering the relative
biological effectiveness), with 5 fractions of sequential boost
irradiation at 2.0 Gy per fraction added for boost-prescribed
patients. Based on our previous dosimetric study, a partially wide
tangential field (PWTF) was selected and generated in the
Pinnacle system as the representative of 3DCRT in this study
(15). Medial and lateral 6-MV tangential fields were used to
target the breast and IMN. The dose fields were normalized in
the same way as the three-field technique photon field. A 6-MV
dose was normalized at a point of the central axis of the fields. If
any part of the heart was included in the tangential fields, a
multileaf collimator was used to shield it from the photon fields.
The humeral head, larynx, and trachea were also shielded by the
multileaf collimator.
For VMAT, double coplanar arc plans were generated on
RayStation (RayStation 5.0.3.17, RaySearch Laboratories AB,April 2021 | Volume 11 | Article 645328
Ko et al. Modern Cardiac Sparing Radiation TechniquesStockholm, Sweden). A linear accelerator with 6-MV photon
beams (Versa HD, Elekta, Sweden) was used in this study. Arcs 1
and 2 were simultaneously rotated in the reverse direction. In
most cases, Arc 1 started at 295–305° and stopped at 155–165°.
All plans were normalized to ensure that at least 95% of the chest
wall PTV received 95% of the prescribed dose. The planning
criteria for PTV coverage and dose to normal organs were based
on institutional practice guidelines. To minimize the occurrence
of hotspots, particularly in the CTV, the maximum dose to any
point was limited to 105%. RayStation was used for dose
calculation and optimization, in a dose grid sized 2 mm with a
collapsed cone algorithm.
Dose constraints followed Danish Breast Cancer Cooperative
Group guidelines and Radiation Therapy Oncology Group 1005
protocol for 3DCRT and HF-VMAT, respectively. However, a
modified protocol constructed from previous studies in our
institution was used. Doses to normal tissues were limited as
follows: an MHD of <5 Gy; a maximum and mean dose to the
LAD of <12 Gy and <5 Gy, respectively; <50%, <35%, and <20%
for the ipsilateral lung volume receiving over 5 Gy (V5Gy), 10 Gy
(V10Gy), and 20 Gy (V20Gy), respectively; and a mean
contralateral lung dose of <2 to 3 Gy. Moreover, wherever
possible, doses to the LAD, heart, and other normal tissues
were kept as low as possible while ensuring PTV coverage. PBT
plans were generated using the pencil beam scanning technique
in Raystation9A (RaySearch Laboratories AB). Two beams,
including one anterior beam and one left oblique beam at an
angle ranging from 30° to 45°, were used. For PBT plans, the area
5 mm inside the boundary of the external contour was excluded
from PTVs to spare the skin, and a margin of 1 mm was added
with respect to the specific distal and proximal beams. Isotropic
5-mm uncertainty and 3.5% range uncertainty were accounted
for in the robust optimization algorithm. Dose criteria were set
based on a combination of the Radiotherapy Comparative
Effectiveness Consortium Trial (RADCOMP) description and
clinical guidelines of the New York Proton Center. At least 95%
of each PTV was expected to receive >95% of the prescribed dose.
The maximum dose to the PTV was restricted to 110% of the
prescribed dose. The MHD was set as <15 Gy and ipsilateral lung
V20Gy was set as <50% to comply with the mandatoryFrontiers in Oncology | www.frontiersin.org 3constraints criteria of RADCOMP (16). However, wherever
possible, an ipsilateral lung V20Gy of <15%, MHD of <2 Gy,
maximum dose to the heart surface of <20 Gy, and maximum
dose to the skin of <95% of the prescribed dose were used as
planning objectives.
Target volume coverage and doses to OARs were calculated
for each RT technique. Target volume coverage was evaluated
with D90 (dose to 90% of the target volume), D95 (dose to 95%
of the target volume), homogeneity index (HI), and conformity
index (CI). D90 and D95 were reported as the percentage of the
prescribed dose, as the prescribed doses differed between
techniques. Composite plans with individual PTVs for the
whole breast, boost, AXL nodes, SCLs, and IMNs were
evaluated separately for each target volume. Doses to the heart,
LAD, ipsilateral lung, contralateral breast, and skin were
calculated for dose evaluation for OARs. The 5-mm zone
inside the boundary of the external contour was considered the
skin area. All 120 plans met the mandatory constraint criteria for
PTVs and OARs, as described. The resulting parameter estimates
were compared using one-way analysis of variance and the
Bonferroni test using R (v.4.0.2, The R Foundation for
Statistical Computing, Vienna, Austria) in RStudio (v.1.3,
RStudio Inc., Boston, MA). p-values of <0.05 were considered
indicative of statistical significance.RESULTS
Representative cross-sectional dose distributions of all eight
techniques in a single patient on the same slice of CT images
are illustrated in Figure 1. Figure 2 depicts the mean dose-
volume histograms of 15 patients for each of the eight techniques
with respect to key PTVs and OARs. The mean values of PTV
coverage and OARs of interest in 15 patients are presented in
Supplementary Table 1.
PTV
Regarding PTV coverage, PBT and VMAT were superior in
terms of D90, D95, HI, and CI to 3DCRT, with either an HF orFIGURE 1 | Representative 2D dose distributions in a patient. (A) 3DCRT-FB-CF, (B) 3DCRT-CPAP-CF, (C) 3DCRT-FB-HF, (D) 3DCRT-CPAP-HF, (E) VMAT-FB-HF,
(F) VMAT-CPAP-HF, (G) PBT-FB-CF, and (H) PBT-CPAP-CF on the same level cut of CT images. 3DCRT, three-dimensional conformal radiotherapy; VMAT, volumetric
modulated arc therapy; PBT, proton beam therapy; CPAP, continuous positive airway pressure; CF, conventional fractionation; HF, hypofractionation.April 2021 | Volume 11 | Article 645328
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between any techniques. In contrast to coverage for the other
nodes, which followed the tendency observed for whole PTV
coverage, PBT achieved greater coverage of IMNs than VMAT,
with statistical significance (in D90 and D95). No significant
difference between the use of CPAP and FB was observed in any
PTV coverage results (Figures 3A, B).Heart
The MHD values varied considerably between techniques. PBT
achieved the lowest MHD of 0.47 Gy. The change in MHD with
the use of CPAP in PBT was non-significant. Except for PBT, the
use of CPAP significantly reduced MHD in every technique in
comparison with corresponding FB conditions. In VMAT with
CPAP, the mean MHD was 2.22 Gy, which was 44% lower than
the corresponding value achieved with VMAT in FB conditionsFrontiers in Oncology | www.frontiersin.org 4(3.95 Gy) and which was non-inferior to that achieved with PBT
in FB conditions (Figure 3C).
LAD
Five techniques, including all four 3DCRT techniques and
VMAT in FB conditions, showed maximum LAD doses of >20
Gy, while the other three techniques achieved doses of <10 Gy.
Among photon-based techniques, only VMAT with CPAP
achieved the maximum LAD dose that was non-inferior to that
achieved by PBT (Figure 3D).
Ipsilateral Lung
VMAT and PBT techniques significantly reduced the mean
ipsilateral lung dose (MLD) compared with that achieved with
3DCRT. Regarding MLD, no significant difference was found





FIGURE 2 | Dose-volume histograms (DVH). (A) PTV, (B) IMN, (C) heart, (D) ipsilateral lung, (E) LAD, (F) skin, (G) esophagus, and (H) contralateral breast. Lines
represent the mean DVH curve of each technique. IMN, internal mammary lymph nodes; LAD, left anterior descending artery; PTV, planning target volume.April 2021 | Volume 11 | Article 645328
Ko et al. Modern Cardiac Sparing Radiation Techniquestechniques with FB. PBT attained the lowest MLD (4.49 Gy),
while VMAT-based techniques achieved an MLD of 6.67 Gy
(Figure 3E).
The percentage of the ipsilateral lung volume receiving over
20 Gy (V20) was lower in VMAT and PBT than in 3DCRT. The
corresponding values were comparable between VMAT and PBT
techniques (approximately 7–9%) (Figure 3F). Figure 4 presents
the estimates of the lowest ipsilateral lung V5 and V10 (volume
receiving >5 Gy and >10 Gy, respectively) achieved with
PBT techniques.Skin
The dose administered to 1% of the volume of the skin (D1%)
was approximately 108–109% in VMAT and PBT, compared to
>112% in 3DCRT. However, there were no significant differences
between techniques.Esophagus
Regarding the esophagus, there was no significant difference in
V20 between techniques. The maximum esophageal dose was
not significantly different between photon techniques, and
VMAT with CPAP resulted in a dose 9.9 Gy lower than PBT
in FB. In terms of mean esophageal dose, PBT achieved the
lowest dose of 1 Gy and VMAT showed the highest with 3.4 Gy
(Figure 3G).Contralateral Breast
VMAT techniques achieved a mean contralateral breast dose of
>2.1 Gy, which was greater than those achieved by the other
techniques. In contrast, PBT techniques achieved a mean
contralateral breast dose of <0.005 Gy, which was lower than
those achieved by the other techniques (Figure 3H). Findings for
the OARs are summarized in Figure 5.Frontiers in Oncology | www.frontiersin.org 5DISCUSSION
Heart-Sparing Efforts in the Era of RNI
Disease-free survival in patients with breast cancer has improved
by 3–5%, according to the results of modern clinical trials
involving RNI, including RNI of SCLs, AXLs, and IMNs (7, 8).
Maximizing the therapeutic efficacy of RNI requires the
improvement of the accuracy of dose delivery to the target
volumes, while sparing the surrounding OARs, which may be
achieved with modern techniques used individually or in
combination. In this study, we compared three RT techniques
(standard 3D photon, VMAT, and PBT) with or without CPAP
delivered in CF or HF schedules to 15 patients with left-sided
breast cancer whose regional nodes were being treated.
IMRT has been proposed as a heart-sparing technique,
although findings regarding MHD have been conflicting. In a
recent prospective study from the Memorial Sloan-Kettering
Cancer Center (17), an MHD of 13.2 Gy (range, 8.6–20 Gy)
was reported in patients with left-sided breast cancer who
received multibeam IMRT. In a Korean dummy-run study
(KROG 1901), 21 institutions received a representative case
and were requested to create a complete RT plan from target
delineation according to respective institutional protocols (18).
Although all submitted plans were generated for IMRT (13 fixed-
field IMRT, 7 VMAT, and 1 helical tomotherapy), the median
MHD was 12.5 Gy with a wide range (3.3–24.1 Gy). In a study by
Pham et al., an MHD of 5.7 Gy was reported with VMAT-
DIBH (19).
IMRT techniques vary in sophistication, and discrepancies in
MHD can be accounted for by several factors. These factors
include differences in methods used for the balancing of target
volume coverage versus the minimization of MHD in the inverse
planning process, the use of the DIBH technique or CPAP, the
use of different fractionation schedules, and inter-physician/
institution variation in target delineation and PTV setupFIGURE 3 | Differences in dose distribution values. Each table represents the difference between techniques in the values of (A) PTV D95 (%), (B) IMN D95 (%),
(C) mean heart dose (Gy), (D) LAD maximum dose (Gy), (E) mean lung dose (Gy), (F) lung V20 (%), (G) esophagus V20 (%), and (H) mean contralateral breast dose (Gy).
Numeric values represent the difference of the value for the technique in the column from the technique in the row. Red cells indicate significant positive differences and
blue cells indicate significant negative differences. IMN, internal mammary lymph nodes; LAD, left anterior descending artery; PTV, planning target volume.April 2021 | Volume 11 | Article 645328
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audits with peer review might help establish best-practice
guidelines for the use of IMRT in breast cancer RT.
HF schedules have become a new standard in breast cancer
RT, particularly in patients with early-stage disease. Although
evidence from a recent randomized trial in China supported the
use of HF schedules in the treatment of locally advanced breast
cancer (20), concerns exist over the safety and efficacy profile of
HF in RNI settings (21). For example, the 40/15 regimen, used in
the present study, is a popular regimen in RNI settings in the
United Kingdom and Korea and was endorsed by the guidelines
issued during the COVID-19 pandemic (12). Moreover, it is
currently being tested in clinical trials in Denmark and France
(NCT02384733 and NCT03127995). Concurrently, in North
America, an HF regimen of >40/15 in 2-Gy equivalent doses is
being tested in randomized trials (Alliance A221505
[NCT03414970] and FABREC [NCT03422003]).Frontiers in Oncology | www.frontiersin.org 63DCRT-FB and PBT at the Opposite Ends
In the present study, 3DCRT (PWTF in this study) in FB
conditions, as the representative conventional treatment, showed
the following dosimetry profile: the D95 of the PTV was 81% of the
prescribed dose, with a CI of 0.52, skin D1% of 113%, maximum
LAD dose of 48 Gy, and MLD of 20 Gy. The MHD of 7.8 Gy was
slightly lower than that previously reported yet consistent with that
presented in studies using wide tangents or matched photon-
electron fields in FB conditions (approximately 9 Gy) (15, 22).
Meanwhile, the discrepancy in findings may be explained by the
reduced coverage of IMN target volumes due to partial heart block
with a PWTF in the current study (D95 75%, D90 80%).
In the present study, PBT was associated with the lowest doses to
most OARs and with the best target volume coverage: the D95 of
the PTV was 98% of the prescribed dose, with a CI of 0.92, IMN
coverage (D95) of 99%, skin D1% of 109%, maximum LAD dose of
6.1 Gy, MLD of 4.5 Gy, and MHD of 0.5 Gy, which were consistentFIGURE 4 | Ipsilateral lung volumes receiving over 5, 20, and 30 Gy per patient per technique.FIGURE 5 | Doses to organs-at-risk per technique, aimed at decreasing the mean heart dose.April 2021 | Volume 11 | Article 645328
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(23, 24). This might be due to the use of two beams, the skin being
clipped out of the PTV, or active OAR-sparing during RT planning.
Nevertheless, the clinical benefit of this excellent dose distribution
remains unclear and subject to scrutiny in multi-center randomized
trials based in North America (RADCOMP; NCT02603341) and
Denmark (The DBCG Proton; NCT04291378).
Standard 3DCRT under FB conditions and PBT are at the
opposite ends of the spectrum in terms of MHD. However, it is
important to assess the impact of modern photon RT techniques
and their relative contributions to any increase in the risk of
long-term side effects, as proton beams are not universally
accessible or cost-effective in the treatment of women without
comorbidities or of those who receive an MHD of <5 Gy (25).
The DBCG proton trial is recruiting patients with indications for
RT, wherein standard RT planning reveals an MHD of >4 Gy.VMAT With CPAP in HF: An Encouraging
Choice
The dosimetric profile of VMAT with CPAP in an HF schedule
reported in the present study is encouraging: the D95 of the PTV
was 96% of the prescribed dose, with a CI of 0.91, IMN coverage
(D95) of 90%, skin D1% of 107%, maximum LAD dose of 7.2 Gy,
left lung V20 of 9%, and MHD of 2.2 Gy. In the FB condition, a
50% reduction in MHD from 7.8 Gy (3DCRT) to 3.9 Gy was
achieved with the use of VMAT. These values are similar to those
previously reported for VMAT with the DIBH technique in a
study in the United Kingdom (PTV nodes 96% and MHD 2.6
Gy), with the exception of the maximum LAD dose (23.3 Gy)
and left lung dose (V17Gy 28%) (24).
Evidence suggests that theMHD can be reduced by 50%with the
use of theDIBH technique (26, 27). In the present study,we observed
a 53% reduction in the MHD due to the use of CPAP (MHD of
3DCRT with CPAP compared with those in 3DCRT under FB
conditions in either CF or HF schedules); this finding was consistent
with those of previous studies. In the present study, the use ofVMAT
with CPAP achieved an additional 40.1% reduction in the MHD
(comparedwith thosewith 3DCRTwithCPAP inCF, from3.7Gy to
2.2Gy). Comparedwith PBT in FB, onlyVMATwithCPAP showed
no significant difference in MHD among photon techniques, which
indicates that the gap between photon and proton RT has narrowed
substantially with modern RT techniques.
Some observations in results were statistically non-significant
but notable. An MHD of 1.77 Gy was observed in VMAT with
CPAP at a pressure of 17 cmH2O (versus 2.6 Gy and 2.3 Gy
achieved at pressures of 15 cmH2O and 12 cmH2O, respectively).
Furthermore, ipsilateral lung V20 was reduced to 9% in VMAT
with CPAP, a result comparable with that of lung-sparing PBT.
In the present study, as a consequence of using the 40/15
regimen instead of the 50/25 regimen, albeit not statistically
significant, the MHD decreased by 1.5 Gy and 0.71 Gy under FB
and CPAP conditions, respectively. The maximum LAD dose
showed a significant reduction of 9.3 Gy and 8.4 Gy with an HF
schedule in FB and CPAP conditions, respectively; this finding is
similar to that reported by Pierre et al. (13). In addition, the 40/15
HF schedule can help reduce the lung dose to a greater extent thanFrontiers in Oncology | www.frontiersin.org 7the 50/25 schedule, a result consistent with that of a previous study
(28). However, the clinical relevance of these dosimetric differences
associated with HF regimens is yet to be elucidated.
Other OARs
Regarding the contralateral breast dose, the present findings are
consistent with those of previous studies (24). Only PBT
techniques were able to spare the contralateral breast tissue,
delivering a dose close to 0 Gy (0.003–0.005 Gy). Although
VMAT significantly increased the dose delivered to the
contralateral breast compared with that delivered by 3DCRT,
the mean dose difference between these techniques was
approximately 1 Gy. According to a recent study based on the
National Cancer Database, which includes data regarding breast
cancer and other tumor types, the relative risk of secondary
cancer associated with IMRT is similar to that associated with
3DCRT (29), suggesting that these dose differences may not
translate to clinically relevant outcomes in most middle-age and
older women.
The esophageal dose was comparable between VMAT and
3DCRT, and significantly lower in photon techniques compared
to PBT. Our findings with respect to proton versus photon are
similar to a recent study by Paganetti et al. (30). However, our
findings with respect to VMAT versus 3DCRT contradicts
previous studies. In one study where the esophagus was not
contoured (31) and another study where the dose-constraint of
the esophagus (Dmax less than 40 Gy) was higher than our
method (D0.03cc less than 12 Gy) (30), the esophageal dose was
higher in patients treated with IMRT compared to patients
treated with 3DCRT. A study by Yaney et al. also showed that
these dosimetric differences translated into an increased rate of
grade 2 esophagitis in patients with IMRT.
Personalized RT Strategies
Overall, these findings suggest that each of the eight techniques can
achieve adequate target volume coverage with varying doses
delivered to OARs, indicating that RT for breast cancer should be
personalized based on each patient’s anatomical characteristics.
Bazan et al. recently reported the potential of an adaptive
treatment planning algorithm for IMRT versus 3DCRT in RNI
settings (32). In the algorithm, IMRT was used in 30% of patients
for whom 3DCRT did not meet the critical OAR constraint criteria.
Moreover, Hytonen et al. recently presented the feasibility of an
automated patient-specific evidence-based decision-making system
for optimizing proton or photon treatment based on normal tissue
complication probability (18). In a simulation of this study, PBTwas
indicated for 22% of the patients, andmultiple patients were close to
the decision threshold at the same time. Taken together, the present
findings may contribute to the development of treatment strategies
for patients with left-sided breast cancer undergoing RNI.Limitations
PBT is not universally accessible and CPAP for breast cancer RT
is presently a novel technique. Since non-contrast CT images
were used in this study, uncertainties in the contouring of LAD
vessels might exist. Moreover, it was not possible to delineate theApril 2021 | Volume 11 | Article 645328
Ko et al. Modern Cardiac Sparing Radiation Techniquesleft ventricle separately on non-contrast CT, and thus we were
unable to evaluate doses to the cardiac substructures (such as the
left ventricle receiving 5 Gy; LV-V5); therefore, the heart was
considered a single organ. Nevertheless, we recently reported a
significant MHD effect per Gy for cardiac toxicity, particularly in
the era of CT-based individual dose calculation in women with
breast cancer (33). The clinical relevance of the dosimetric
differences found in this study is yet to be elucidated.CONCLUSION
Among available techniques, modern PBT can achieve the lowest
doses to most OARs in the regional nodal treatment of left-sided
breast cancer. The gap in the MHD between proton and photon
RT has narrowed substantially with modern techniques. In
VMAT-HF with CPAP, an MHD and maximum LAD dose of
approximately 2 Gy and 7 Gy, respectively, were achieved with
adequate target volume coverage and a reduced lung dose (V20
9%, MLD 6 Gy). The clinical relevance of these dosimetric
differences is yet to be elucidated. This study provides a precise
dosimetric comparison between modern breast RT techniques to
assist institutions in selecting the optimal RT regimens based on
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